hVIVO (LON:HVO) Trading Down 48.6% – Should You Sell?

hVIVO plc (LON:HVO) fell 48.6% during mid-day trading on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.32 ($0.11). 74,283,875 shares were traded during mid-day trading, an increase of 2,124% from the average session volume of 3,339,384 shares. The stock had previously closed at GBX 16.20 ($0.22).

Wall Street Analysts Forecast Growth

Separately, Shore Capital reiterated a “buy” rating on shares of hVIVO in a report on Thursday, April 10th.

hVIVO Stock Performance

The stock has a fifty day simple moving average of GBX 16.30 and a two-hundred day simple moving average of GBX 18.26. The company has a debt-to-equity ratio of 33.86, a quick ratio of 1.16 and a current ratio of 1.61. The stock has a market capitalization of £65.38 million, a price-to-earnings ratio of 3.81 and a beta of 0.97.

hVIVO (LON:HVO) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Analysts forecast that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Insider Activity at hVIVO

In other hVIVO news, insider Yamin Mo’ Khan sold 3,062,246 shares of hVIVO stock in a transaction on Thursday, March 6th. The shares were sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($702,634.39). 14.03% of the stock is owned by corporate insiders.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.